secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001437749-24-026385
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Q2 cash $218.7M; PIPE-307 Phase 2 enrollment on track
---------------------------------------------------------------

- Cash, equivalents and marketable securities $218.7M at June 30, 2024, up from $125.2M at year-end 2023.
- R&D expenses $7.9M vs $9.5M YoY; G&A expenses $3.0M vs $1.6M YoY.
- Completed IPO in April 2024, net proceeds $107.9M.
- Phase 2 VISTA trial of PIPE-307 for RRMS enrollment on track, completion expected in 2025.
- Strengthened board and management with four new appointments, including Troy Ignelzi and Sarah Boyce.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924026385/0001437749-24-026385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924026385/cont20240719c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-026385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer